02171 CARSGEN-B
- 3.060
- -0.020-0.65%
CARSGEN-B News
CARSGEN-B: INTERIM REPORT 2024
Koji Pharmaceutical - B (02171) fell by 59.60%, now reported at 2.69 yuan, hitting a 52-week low.
As of 11:46, Keji Pharmaceutical - B (02171) fell 59.60% compared to the previous closing price, now at 2.690 yuan, hitting a 52-week low; volume of 3.6526 million shares, with a turnover of 9.8273 million Hong Kong dollars.
CARsgen Therapeutics Holdings Limited's (HKG:2171) Stock Price Dropped 26% Last Week; Individual Investors Would Not Be Happy
CARsgen Announces 2024 Interim Results
CARsgen Therapeutics Holdings Books Narrower Attributable Loss in H1
Kesi Pharmaceuticals releases 2024 mid-term performance.
Shanghai, August 29, 2024 /PRNewswire/ -- Koji Pharmaceutical (Stock Code: 2171.HK), a company mainly focused on innovative CAR-T cell therapy for the treatment of hematologic malignancies and solid tumors, has released its 2024 interim performance highlights. Performance Highlights Quick Glance: Saicaize approved by the National Medical Products Administration for listing Completion of patient enrollment for the confirmatory Phase II trial of Shurijiolunsa injection (CT041) in China Active progress in multiple solid tumor CAR-T adjuvant therapy studies Clinical data of Shurijiolunsa injection, Saicaize, and CT071 presented at academic conferences.
Keji Pharmaceutical-B (02171) released its interim performance, with a shareholder's attributable loss of 0.352 billion yuan, a 13.08% narrowing year-on-year.
Kozy Pharmaceutical-B (02171) released its interim results for the six months ended June 30, 2024, during which time the group...
Express News | CARsgen Therapeutics Holdings H1 Capex RMB 6 Million
Express News | CARsgen Therapeutics Holdings H1 Adjusted Net Income RMB -342 Million
CARSGEN-B: ANNOUNCEMENT OF INTERIM RESULTSFOR THE SIX MONTHS ENDED JUNE 30, 2024
Express News | CARsgen Announces Enrollment Completion in China GC/Gej Pivotal Phase II Clinical Trial of the First-in-Class Claudin18.2 Car T (Satri-Cel)
CARsgen Therapeutics Completes Phase II Clinical Trial Enrollments for Solid Tumors Drug
The China-based clinical trial of the Claudin18.2 CAR-T therapy ShuRuiJi Oulansi injection, the world's first of its kind developed by Keji Pharmaceutical, for confirmed stage II gastric cancer patients has completed enrollment.
Shanghai, August 19, 2024 / PRNewswire / - Kojie Pharmaceutical (stock code: 2171.HK), an innovative CAR-T cell therapy company that focuses on treating hematological malignancies and solid tumors, announced that CT041 (a self-targeting Claudin18.2 CAR-T cell candidate product) - shrudge base Orlans injection (development code: CT041), a Phase II clinical trial for advanced gastric/esophageal gastric junction adenocarcinoma in China, has completed enrollment and randomization of all subjects according to the clinical protocol. The trial is an open-label study conducted in China.
Kaiser Pharmaceuticals-B (02171.HK): Clinical Phase II trials of Surojelone Injection, a China-confirmed drug, have completed enrollment.
KCH August 19th | Koji Pharmaceutical-B (02171.HK) issued an announcement stating that the IIa clinical trial of Shuruijiaoluensai injection (research and development code: CT041, a targeting Claudin18.2 autologous CAR-T cell candidate product) being conducted in China has completed enrollment and randomization according to the clinical plan. The trial is an open-label, multicenter, randomized controlled clinical trial conducted in China, aimed at evaluating Shuruijiaoluensai injection for the treatment of advanced gastric/esophageal junction adenocarcinoma with positive expression of Claudin18.2 and a history of failure of at least 2 treatments.
Kojie Pharmacy-B (02171.HK) plans to hold a board of directors meeting on August 28 to approve its interim performance.
Kaiji Pharmaceutical-B (02171.HK) announced on August 15th that the board of directors meeting will be held on Wednesday, August 28th, 2024, to consider and approve the group's interim performance for the six months ending June 30th, 2024, as well as to handle other matters.
CARSGEN-B: DATE OF BOARD MEETING
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
On June 28, Keji Pharmaceutical -B (02171.HK) spent HKD 720,000 to repurchase 150,000 shares.
On June 28th, Keji Pharmaceutical -B (02171.HK) announced that it had spent HKD 720,000 to repurchase 150,000 shares.
CARsgen Therapeutics' Substantial Shareholder Boosts Stake to 37.78%
Kangji Pharmaceutical (02171) under Hong Kong Stock Connect: the major shareholder has increased shareholding by 1.9 million shares, and the company has repurchased 3.98 million shares.
Jingu Finance News | Koji Pharmaceutical (02171) announced that the board of directors was informed by Yijie Biology that the Yijie concerted action group has purchased a total of 1.9035 million shares of the company's stock within this year until June 25, 2024 (after the close of trading), accounting for approximately 0.33% of the total issued shares. After increasing its shareholding, the Yijie concerted action group holds 217 million shares of the company's stock, accounting for approximately 37.78% of the total issued shares. In addition, as of the close of trading on June 25, 2024, the company has repurchased a total of 3.9855 million shares of its own stock, accounting for approximately 0.69% of the total issued shares. The funds used to repurchase the shares are from...
Analysis
Price Target
No Data
No Data